PTPN11 and juvenile myelomonocytic leukemia: In the past 20 years, SHP2 has been reported to participate in developmental diseases, such as Noonan syndrome, metachondromatosis, and malignancies such as juvenile myelomonocytic leukemia (Zhang et al., 2015).